Top

Published in:

01-05-2012 | Interventional

Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (>7 cm) tumours

Authors: Federico Collettini, Dirk Schnapauff, Alexander Poellinger, Timm Denecke, Eckart Schott, Thomas Berg, Peter Wust, Bernd Hamm, Bernhard Gebauer

Published in: European Radiology | Issue 5/2012

Abstract

Objectives

Evaluate the clinical outcome of CT-guided high-dose-rate-brachytherapy (CT-HDRBT) of hepatocellular carcinoma (HCC) larger than 5 cm in diameter with the goal of local tumour control (LTC).

Methods

Thirty-five patients with 35 unresectable HCCs ranging in size from 5 to 12 cm (mean: 7.1 cm) were treated with CT-HDRBT. Tumours were classified into two groups according to diameter: “large lesions” (5–7 cm) and “very large lesions” (>7 cm). Tumour response was evaluated by Gd-EOB-DTPA-enhanced liver magnetic resonance imaging (MRI) performed before, 6 weeks after, and then every 3 months after treatment. Endpoints included local tumour control (LTC), progression-free survival (PFS) and overall survival (OS).

Results

Nineteen tumours were classified as “large” and 16 as “very large”. Complete tumour enclosure was achieved in all patients after the first CT-HDRBT session. Five patients were lost to follow-up. At a mean follow-up of 12.8 months, two patients had local progression (6.7%), one in each group. Nine patients (30%) experienced distant progression, five (26.3%) in the “large” and four (25%) in the “very large” group. No patients died during the follow-up period. No major complications were recorded.

Conclusions

CT-HDRBT is a promising therapy for HCCs that exceed indications for thermal ablation.

Key Points

• Computed Tomography guided high-dose-rate brachytherapy offers new therapeutic options for hepatocellular carcinoma

• CT-HDRBT can be safely practised in HCCs exceeding 5 cm in diameter

• CT-HDRBT offers high rate of local control where thermal ablation is impossible

• CT-HDRBT could be a valid alternative to TACE for intermediate stage HCC

Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373(9664):614–6PubMedCrossRef

Lencioni R (2010) Loco-regional treatment of hepatocellular carcinoma. Hepatology 52:762–73PubMedCrossRef

Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK (2000) Treatment of intrahepatic malignancy with radiofrequency ablation. Cancer 88:2452–2463PubMedCrossRef

Goldberg SN (2002) Comparison of techniques for image-guided ablation of focal liver tumors. Radiology 223:304–307PubMedCrossRef

Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J et al (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234:961–7PubMedCrossRef

Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M et al (1993) Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 8:1121–1126

Gournay J, Tchuenbou J, Richou C, Masliah C, Lerat F, Dupas B et al (2002) Percutaneous ethanol injection vs resection in patients with small single hepatocellular carcinoma: a retrospective case–control study with cost analysis. Aliment Pharmacol Ther 16:1529–1538PubMedCrossRef

Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243:321–8PubMedCrossRef

Ricke J, Wust P, Stohlmann A, Beck A, Cho CH, Pech M et al (2004) CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 58:1496–505PubMedCrossRef

10.

Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R et al (2010) Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 78:172–9PubMedCrossRef

11.

Ricke J, Wust P, Stohlmann A, Beck A, Cho CH, Pech M et al (2004) CT-Guided brachytherapy. A novel percutaneous technique for interstitial ablation of liver metastases. Strahlenther Onkol 180:274–80PubMedCrossRef

12.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

13.

Ricke J, Thormann M, Ludewig M, Jungnickel K, Grosser O, Wybranski C et al (2010) MR-guided liver tumor ablation employing open high-field 1.0 T MRI for image-guided brachytherapy. Eur Radiol 20:1985–93PubMedCrossRef

14.

Goldberg SN, Grassi CJ, Cardella JF, for the Society of Interventional Radiology et al (2009) Technology Assessment Committee and the International Working Group on Image-guided Tumor Ablation. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20:S377–90PubMedCrossRef

15.

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–9PubMedCrossRef

16.

Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10:35–43PubMedCrossRef

17.

Ayav A, Germain A, Marchal F, Tierris I, Laurent V, Bazin C et al (2010) Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence. Am J Surg 200:435–9PubMedCrossRef

18.

Huang J, Hernandez-Alejandro R, Croome KP, Yan L, Wu H, Chen Z et al (2011) Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in childs A Cirrhotics-a retrospective study of 1,061 Cases. J Gastrointest Surg 15:311–20PubMedCrossRef

19.

Yin XY, Xie XY, Lu MD, Xu HX, Xu ZF, Kuang M et al (2009) Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer 115:1914–23PubMedCrossRef

20.

Crocetti L, de Baere T, Lencioni R (2010) Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 33:11–7PubMedCrossRef

21.

Yang WZ, Jiang N, Huang N, Huang JY, Zheng QB, Shen Q (2009) Combined therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation for small hepatocellular carcinoma. World J Gastroenterol 15:748–52PubMedCrossRef

22.

Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G (2006) Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 16:661–9PubMedCrossRef

23.

Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–27PubMedCrossRef

24.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–90PubMedCrossRef

25.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34PubMedCrossRef

26.

Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–9PubMedCrossRef

27.

Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–7PubMedCrossRef

28.

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52PubMedCrossRef

29.

Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF et al (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49:1185–1193PubMedCrossRef

30.

Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J et al (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21:224–230PubMedCrossRef

31.

Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S et al (2011) Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across barcelona clinic liver cancer stages: A European evaluation. Hepatology 26. doi:10.1002/hep.24451

32.

Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G et al (2008) Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 31:1141–9PubMedCrossRef

33.

Takeda A, Takahashi M, Kunieda E, Takeda T, Sanuki N, Koike Y et al (2008) Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: Preliminary results for efficacy and toxicity. Hepatol Res 38:60–69PubMedCrossRef

34.

Louis C (2010) Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 9(5):479–87PubMed

35.

Seo YS, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH et al (2010) Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102:209–14PubMedCrossRef

36.

Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J et al (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26:657–664PubMedCrossRef

37.

Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma <4 cm. Gastroenterology 127:1714–1723PubMedCrossRef

38.

Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541–51PubMedCrossRef

39.

Wieners G, Pech M, Wust P, Miersch A, Streitparth F, Berg T et al (2005) CT-gestützte Brachytherapie bei hepatozellulärem Karzinom (HCC): Ergebnisse einer prospektiven Phase-II-Studie. Fortschr Röntgenstr doi:. doi:10.1055/s-2005-867648

40.

Mohnike K, Wieners G, Pech M, Seidensticker M, Rühl R, Lopez-Haenninen E et al (2009) Image-guided interstitial high-dose-rate brachytherapy in hepatocellular carcinoma. Dig Dis 27:170–4PubMedCrossRef

Title: Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (>7 cm) tumours
Authors: Federico Collettini
Dirk Schnapauff
Alexander Poellinger
Timm Denecke
Eckart Schott
Thomas Berg
Peter Wust
Bernd Hamm
Bernhard Gebauer
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: European Radiology / Issue 5/2012
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-011-2352-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (>7 cm) tumours

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 5/2012

Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results

Lung neovascularity in pulmonary arterial hypertension associated with congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients

Left and right ventricle assessment with Cardiac CT: validation study vs. Cardiac MR

In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy

Clinical indications for musculoskeletal ultrasound: A Delphi-based consensus paper of the European society of musculoskeletal radiology

Diffusion tensor imaging applications in multiple sclerosis patients using 3T magnetic resonance: a preliminary study